PT 141 (Bremelanotide) is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone (α-MSH) that functions as a melanocortin receptor agonist . As a non-hormonal research compound, PT-141 represents a distinct class of peptide with a unique mechanism of action primarily targeting the central nervous system .
Developed from the tanning peptide Melanotan II, PT 141 was engineered to activate melanocortin receptors—particularly MC3R and MC4R—which are expressed primarily in the central nervous system and are involved in various physiological pathways including sexual function and energy homeostasis . In 2019, bremelanotide received FDA approval for clinical use in premenopausal women with hypoactive sexual desire disorder (HSDD) under the brand name Vyleesi .
Mechanism of Action
PT-141 functions as an agonist at multiple melanocortin receptors. The order of potency is MC1R > MC4R > MC3R > MC5R > MC2R . This peptide acts on the central nervous system to exert its effects, rather than through peripheral vascular mechanisms .
Key Research Applications:
-
Melanocortin receptor signaling and pathway studies
-
Neurological research involving hypothalamic and limbic system activation
-
Sexual function and behavior research models
-
Central nervous system receptor pharmacology
PT 141 Product Specifications
| Parameter | Specification |
|---|---|
| Product Name | PT-141 (Bremelanotide) |
| Synonyms | PT-141, Bremelanotide, PT141, Vyleesi |
| CAS Number (Free Base) | 189691-06-3 |
| Molecular Formula | C₅₀H₆₈N₁₄O₁₀ |
| Molecular Weight | ~1025.18 g/mol |
| Sequence Short | Ac-Nle-cyclo(DHfRWK)-OH (f = D-Phe) |
| Sequence (Full) | Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys (Asp2-Lys7 bridge) |
| Purity | ≥99% (by HPLC area) |
| Form | White to off-white lyophilized powder |
| Peptide Content | ≥70% |
| Water Content | ≤5.0% |
| Endotoxin Level | <0.25 EU/mg |
| Storage | ≤ -20°C (long-term); 2-8°C (short-term), protected from light and moisture |
Quality Assurance
Every batch of PT 141 undergoes rigorous analytical testing to ensure maximum purity and research integrity:
| Test | Method | Specification |
|---|---|---|
| Identity | ESI-MS | Matches theoretical mass |
| Purity | RP-HPLC | ≥99% area |
| Sequence Confirmation | MS/MS | 100% sequence coverage |
| Water Content | Karl Fischer | ≤5.0% |
| Endotoxin | LAL Test | <0.25 EU/mg |
Certificate of Analysis (COA) available upon request.
Storage & Reconstitution Guidelines
Storage Conditions:
-
Lyophilized (Long-term): -20°C, protected from light and moisture
-
Lyophilized (Short-term): 2°C – 8°C (refrigerated)
-
Reconstituted: 4°C for up to 30 days (with bacteriostatic water) ; avoid repeated freeze-thaw cycles
Reconstitution Protocol:
-
Allow vial to reach room temperature
-
Add sterile bacteriostatic water or 0.9% sodium chloride solution
-
Gently swirl (do not vortex) until fully dissolved
-
Allow solution to stand at 4°C for complete reconstitution
Note: Peptides are sensitive to formulation, process, and environmental conditions that may lead to aggregation and degradation.
Research Background
Development History
PT-141 was developed from the research peptide Melanotan II. While the parent compound was investigated for skin tanning properties through melanogenesis stimulation, PT-141 was specifically designed to dissociate the libido-enhancing effects from the skin-pigmenting activity . Research has demonstrated that PT-141 activates melanocortin receptors MC1R and MC4R to exert its effects, and it is notable for its lack of skin-tanning properties .
Preclinical Studies
-
Administration of PT 141 to rats and nonhuman primates results in penile erections
-
Systemic administration activates neurons in the hypothalamus, as shown by increased c-Fos immunoreactivity
-
Neurons in the same CNS regions take up pseudorabies virus injected into the corpus cavernosum of the rat penis, indicating involvement in the erectile pathway
Clinical Research Status
-
Intranasal administration (4-20 mg) to healthy male volunteers resulted in a dose-dependent increase in erectile activity
-
In patients with mild-to-moderate erectile dysfunction, PT-141 significantly increased the duration of erectile activity compared to placebo
-
FDA-approved under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women (2019)
Important Notice
⚠️ FOR RESEARCH USE ONLY
This product is not intended for human consumption, diagnostic use, therapeutic application, or clinical administration. PT-141 is a research chemical intended exclusively for in-vitro and laboratory research purposes.
-
Not a dietary supplement, food additive, or pharmaceutical for over-the-counter purchase
-
Intended solely for qualified researchers and scientific institutions
By purchasing this product, you confirm that you are a licensed researcher or laboratory professional and agree to use this compound in compliance with all applicable local, national, and international regulations.
Why Choose PeptidesUnit.com?
| PT 141 Feature | PT 141 Benefit |
|---|---|
| ✅ Premium Purity | ≥99% HPLC-verified purity guaranteed |
| ✅ Research-Grade Quality | Manufactured under GMP-aligned conditions |
| ✅ Third-Party Tested | Independent COA for every batch |
| ✅ Secure Packaging | Lyophilized in amber glass vials with tamper-evident seals |
| ✅ Fast Global Shipping | Discreet packaging with real-time tracking |
| ✅ Competitive Pricing | Direct-from-manufacturer pricing |
Order Now
PT 141 (Bremelanotide) Peptide 5mg – ≥99% Purity
Available for immediate shipment
🛒 BUY NOW at PeptidesUnit.com
For bulk orders (10+ vials), custom peptide synthesis, or wholesale inquiries, please contact our sales team at sales@peptidesunit.com. PT 141




Reviews
There are no reviews yet